Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

Autor: Motzer, Robert J., Choueiri, Toni K., Hutson, Thomas, Young Rha, Sun, Puente, Javier, Lalani, Aly-Khan A., Winquist, Eric, Eto, Masatoshi, Basappa, Naveen S., Tannir, Nizar M., Vaishampayan, Ulka, Bjarnason, Georg A., Oudard, Stéphane, Grünwald, Viktor, Burgents, Joseph, Xie, Ran, McKenzie, Jodi, Powles, Thomas

Publikováno v: In European Urology July 2024 86(1):4-9

International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1).

Autor: Yoshida, Kazuhiro, Yasufuku, Itaru, Terashima, Masanori, Young Rha, Sun, Moon Bae, Jae, Li, Guoxin, Katai, Hitoshi, Watanabe, Masahiko, Seto, Yasuyuki, Hoon Noh, Sung, Kwang Yang, Han‐, Ji, Jiafu, Baba, Hideo, Kitagawa, Yuko, Morita, Satoshi, Nishiyama, Masahiko, Kodera, Yasuhiro

Publikováno v: Annals of Gastroenterological Surgery; Mar2022, Vol. 6 Issue 2, p227-240, 14p

Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma.

Autor: Kim, Hye Ryun, Ha Cheon, Seong, Lee, Kwang-Hun, Ryun Ahn, Jung, Jeung, Hei-Cheul, Sook Lee, Sung, Cheol Chung, Hyun, Hoon Noh, Sung, Young Rha, Sun

Publikováno v: International Journal of Hyperthermia; Jun2010, Vol. 26 Issue 4, p305-315, 11p, 1 Diagram, 4 Charts, 2 Graphs

Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression

Autor: Sik Lee, Kyong, Young Rha, Sun, Joong Kim, Sea, Hang Kim, Joo, Kyong Roh, Jae, Soo Kim, Byung, Cheol Chung, Hyun

Publikováno v: Clinical and Experimental Metastasis; November 1996, Vol. 14 Issue: 6 p512-519, 8p

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.

Autor: Bergerot C; Instituto Unity de Ensino e Pesquisa, Centro de Câncer de Brasília, Brasília, DF, Brazil., Young Rha S; Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Pal S; Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Koralewski P; Szpital Specjalistyczny Ludwika Rydygiera, Kraków, Poland., Stroyakovskiy D; Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow, Russia., Alekseev B; P.A. Hertzen Moscow Oncological Research Institute, Moscow, Russia., Parnis F; University of Adelaide, Adelaide, South Australia, Australia., Castellano D; 12 de Octubre University Hospital, Madrid, Spain., Lyun Lee J; Asan Medical Center, Seoul, Republic of Korea.; University of Ulsan College of Medicine, Seoul, Republic of Korea., Sunela K; Department of Oncology, Tampere University Hospital, Tampere, Finland., Ciuleanu T; Prof Dr Ion Chiricuta Cancer Institute and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Heng D; Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada., Glen H; Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK., Wang J; RTI Health Solutions, Research Triangle Park, NC, USA., Bennett L; RTI Health Solutions, Research Triangle Park, NC, USA., Pan J; Eisai, Inc., Nutley, NJ, USA., O'Hara K; Eisai Europe Ltd., Hertfordshire, UK., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.

Publikováno v: The oncologist [Oncologist] 2023 Jan 18; Vol. 28 (1), pp. 59-71.